Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GRN | P28799 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 11/20 | 0.36 |
| ▸ | CA2 | P00918 | 11/20 | 0.36 |
| ▸ | CA9 | Q16790 | 6/20 | 0.35 |
| ▸ | CA12 | O43570 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 4/20 | 0.34 |
| ▸ | CA5A | P35218 | 4/20 | 0.34 |
| ▸ | CA7 | P43166 | 4/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 3/20 | 0.34 |
| ▸ | CA3 | P07451 | 3/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28388247 | 0.98 | KDM4E (0.49) | KDM4EGRNSORT1PHGDHCA1 | |
| SCHEMBL12967530 | 0.84 | GRN (0.51) | KDM4EGRNSORT1PHGDHCA1 | |
| SCHEMBL20743166 | 0.83 | KDM4E (0.33) | KDM4EGRNSORT1PHGDHCA1 | |
| SCHEMBL19508023 | 0.81 | ALDH1A1 (0.40) | KDM4ECA1CA2CA9CA12 | |
| SCHEMBL18029745 | 0.81 | CA12 (0.33) | KDM4EGRNSORT1PHGDHCA1 | |
| SCHEMBL12967531 | 0.81 | GRN (0.49) | KDM4EGRNSORT1PHGDHCA1 | |
| SCHEMBL23328665 | 0.79 | CA12 (0.41) | KDM4ECA1CA2CA9CA12 | |
| SCHEMBL20757925 | 0.78 | CA12 (0.43) | KDM4ECA1CA2CA9CA12 | |
| SCHEMBL18007604 | 0.78 | LMNA (0.46) | KDM4ECA1CA2CA9CA12 | |
| SCHEMBL20760989 | 0.77 | CA12 (0.32) | PHGDHCA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-03-28 | — | — | US | disclosed |
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-01-03 | — | — | US | disclosed |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210122739-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-04-29 | — | — | US | disclosed |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | KDM4E 1791/4885GRN 3735/4885SORT1 2591/4885 |
| US-20210122739-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, PYCARD, NOD1 | KDM4E 1838/4885GRN 3447/4885SORT1 1588/4885 |
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, PYCARD | KDM4E 2097/4885GRN 3030/4885SORT1 1230/4885 |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | KDM4E 2672/4885GRN 2768/4885SORT1 1566/4885 |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | KDM4E 2097/4885GRN 3030/4885SORT1 1230/4885 |
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | KDM4E 2672/4885GRN 2768/4885SORT1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.